adenine has been researched along with Duncan Disease in 15 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Limited data have been published about the infection risk associated with these new drugs, therefore this study analyzes the infectious complications in patients with lymphoproliferative diseases (LPD) treated with monoclonal antibodies (obinutuzumab, ofatumumab, brentuximab, nivolumab, or pembrolizumab), BTK inhibitors (ibrutinib and acalabrutinib), PI3K inhibitors (idelalisib) and BCL2 inhibitors (venetoclax)." | 4.02 | Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study. ( Alonso, C; Ángel Hernández-Rivas, J; Bastidas, G; Bastos-Oreiro, M; Bocanegra, A; Carpio, C; Comai, A; Cordoba, R; De Nicolás, R; Del Campo, R; Fernández-Cruz, A; García-Suárez, J; Grande, C; Jiménez-Ubieto, A; López-Guillermo, A; López-Jiménez, J; Luis Plana, J; Marquet, J; Martín, X; Martínez-López, J; Mas-Ochoa, C; Morillo, D; Navarro-Matilla, B; Núñez, L; Prat, M; Romero, S; Ruiz-Camps, I; Seri, C; Serna, Á; Stefania Infante, M; Vásquez, L; Villafuerte, P, 2021) |
| "We describe the opportunistic infections occurring in 362 patients with lymphoproliferative disorders treated with ibrutinib and idelalisib in clinical practice." | 4.02 | Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study. ( Busca, A; Candoni, A; Cattaneo, C; Dargenio, M; Facchinelli, D; Fanci, R; Farina, F; Laurenti, L; Lessi, F; Marchesi, F; Marchesini, G; Nadali, G; Pagano, L; Picardi, M; Prezioso, L; Spolzino, A; Tisi, MC; Trastulli, F; Verga, L; Visentin, A, 2021) |
| "She was diagnosed with cold agglutinin disease (CAD) and treated with corticosteroids." | 1.62 | [Small B-cell neoplasm responding to ibrutinib after 17 years of cold agglutinin disease symptom]. ( Haga, H; Hishizawa, M; Hori, T; Iga, Y; Kondo, T; Masuda, K; Morimoto, S; Morita, M; Shindo, T; Takaori-Kondo, A; Yamashita, K; Yurugi, K, 2021) |
| " However, BTKi have a range of drug-drug and drug-food interactions, which may alter drug efficacy and/or increase toxicity." | 1.56 | Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management. ( Fancher, KM; Pappacena, JJ, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 7 (46.67) | 2.80 |
| Authors | Studies |
|---|---|
| Stefania Infante, M | 1 |
| Fernández-Cruz, A | 1 |
| Núñez, L | 1 |
| Carpio, C | 1 |
| Jiménez-Ubieto, A | 1 |
| López-Jiménez, J | 1 |
| Vásquez, L | 1 |
| Del Campo, R | 1 |
| Romero, S | 1 |
| Alonso, C | 1 |
| Morillo, D | 1 |
| Prat, M | 1 |
| Luis Plana, J | 1 |
| Villafuerte, P | 1 |
| Bastidas, G | 1 |
| Bocanegra, A | 1 |
| Serna, Á | 1 |
| De Nicolás, R | 1 |
| Marquet, J | 1 |
| Mas-Ochoa, C | 1 |
| Cordoba, R | 1 |
| García-Suárez, J | 1 |
| Comai, A | 1 |
| Martín, X | 1 |
| Bastos-Oreiro, M | 1 |
| Seri, C | 1 |
| Navarro-Matilla, B | 1 |
| López-Guillermo, A | 1 |
| Martínez-López, J | 1 |
| Ángel Hernández-Rivas, J | 1 |
| Ruiz-Camps, I | 2 |
| Grande, C | 1 |
| Morimoto, S | 1 |
| Shindo, T | 1 |
| Iga, Y | 1 |
| Morita, M | 1 |
| Yurugi, K | 1 |
| Masuda, K | 1 |
| Hori, T | 1 |
| Hishizawa, M | 1 |
| Kondo, T | 1 |
| Yamashita, K | 1 |
| Haga, H | 1 |
| Takaori-Kondo, A | 1 |
| Los-Arcos, I | 1 |
| Aguilar-Company, J | 1 |
| Kallam, A | 1 |
| Hansen, N | 1 |
| Bierman, P | 1 |
| Fancher, KM | 1 |
| Pappacena, JJ | 1 |
| Marchesini, G | 1 |
| Nadali, G | 1 |
| Facchinelli, D | 1 |
| Candoni, A | 1 |
| Cattaneo, C | 1 |
| Laurenti, L | 1 |
| Fanci, R | 1 |
| Farina, F | 1 |
| Lessi, F | 1 |
| Visentin, A | 2 |
| Marchesi, F | 1 |
| Prezioso, L | 1 |
| Spolzino, A | 1 |
| Tisi, MC | 1 |
| Trastulli, F | 1 |
| Picardi, M | 1 |
| Verga, L | 1 |
| Dargenio, M | 1 |
| Busca, A | 1 |
| Pagano, L | 1 |
| Law, SC | 1 |
| Hoang, T | 1 |
| O'Rourke, K | 1 |
| Tobin, JWD | 1 |
| Gunawardana, J | 1 |
| Loo-Oey, D | 1 |
| Bednarska, K | 1 |
| Merida de Long, L | 1 |
| Sabdia, MB | 1 |
| Hapgood, G | 1 |
| Blyth, E | 1 |
| Clancy, L | 1 |
| Hennig, S | 1 |
| Keane, C | 1 |
| Gandhi, MK | 1 |
| Regan, JA | 1 |
| Cao, Y | 1 |
| Dispenza, MC | 1 |
| Ma, S | 1 |
| Gordon, LI | 1 |
| Petrich, AM | 1 |
| Bochner, BS | 1 |
| Xu, RA | 1 |
| Wen, J | 1 |
| Tang, P | 1 |
| Wang, C | 1 |
| Xie, S | 1 |
| Zhang, BW | 1 |
| Zhou, Q | 1 |
| Cai, JP | 1 |
| Hu, GX | 1 |
| Cheng, C | 1 |
| Woronow, D | 1 |
| Nayernama, A | 1 |
| Wroblewski, T | 1 |
| Jones, SC | 1 |
| Campello, E | 1 |
| Scomazzon, E | 1 |
| Spiezia, L | 1 |
| Imbergamo, S | 1 |
| Pravato, S | 1 |
| Piazza, F | 1 |
| Semenzato, G | 1 |
| Simioni, P | 1 |
| Trentin, L | 1 |
| Schwarzbich, MA | 1 |
| Witzens-Harig, M | 1 |
| Viganò, M | 1 |
| Mangia, G | 1 |
| Lampertico, P | 1 |
| Berglöf, A | 1 |
| Hamasy, A | 1 |
| Meinke, S | 1 |
| Palma, M | 1 |
| Krstic, A | 1 |
| Månsson, R | 1 |
| Kimby, E | 1 |
| Österborg, A | 1 |
| Smith, CI | 1 |
| Cabras, MG | 1 |
| Angelucci, E | 1 |
4 reviews available for adenine and Duncan Disease
| Article | Year |
|---|---|
Risk of infection associated with new therapies for lymphoproliferative syndromes.
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agent | 2020 |
Ibrutinib.
Topics: Adenine; Animals; Antineoplastic Agents; B-Lymphocytes; Humans; Lymphoproliferative Disorders; Piper | 2014 |
Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.
Topics: Adenine; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine- | 2014 |
Targets for Ibrutinib Beyond B Cell Malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Atrial Fibrillation; Humans; Leukemia, Lympho | 2015 |
11 other studies available for adenine and Duncan Disease
| Article | Year |
|---|---|
Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study.
Topics: Adenine; Adolescent; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies | 2021 |
[Small B-cell neoplasm responding to ibrutinib after 17 years of cold agglutinin disease symptom].
Topics: Adenine; Aged; Anemia, Hemolytic, Autoimmune; Female; Humans; Lymphoproliferative Disorders; Neoplas | 2021 |
Central Nervous System Post-transplant Lymphoproliferative Disorder: Response to Ibrutinib.
Topics: Adenine; Central Nervous System; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; P | 2020 |
Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Citrus paradisi; Citrus sinensis; Comorbid | 2020 |
Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Bacterial Infections; Case-Co | 2021 |
Successful treatment of Epstein-Barr virus-associated primary central nervous system lymphoma due to post-transplantation lymphoproliferative disorder, with ibrutinib and third-party Epstein-Barr virus-specific T cells.
Topics: Adenine; Central Nervous System; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Lympho | 2021 |
Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Allergens; Anti-Allergic Agents; Basophils; Huma | 2017 |
Functional Characterization of 22 CYP3A4 Protein Variants to Metabolize Ibrutinib In Vitro.
Topics: Adenine; Antineoplastic Agents; Cytochrome P-450 CYP3A; Enzyme Assays; Humans; Lymphoproliferative D | 2018 |
Ibrutinib-associated ventricular arrhythmia in the FDA Adverse Event Reporting System.
Topics: Adenine; Adverse Drug Reaction Reporting Systems; Aged; Arrhythmias, Cardiac; Drug Monitoring; Femal | 2018 |
Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases.
Topics: Adenine; Aged; Aged, 80 and over; Atrial Fibrillation; Dabigatran; Female; Humans; Lymphoproliferati | 2018 |
Ibrutinib: another weapon in our arsenal against lympho-proliferative disorders.
Topics: Adenine; Antineoplastic Agents; Humans; Lymphoproliferative Disorders; Piperidines; Pyrazoles; Pyrim | 2015 |